Left ventricular mass and cardiothoracic index in patients with chronic renal disease on hemodialysis by Costa, Francisco de Assis et al.
Original article
171
Left ventricular mass and cardiothoracic index in patients 
with chronic renal disease on hemodialysis
Authors
Francisco de Assis Costa1,2
Rui Manuel dos Santos 
Póvoa1
André Falcão Pedrosa 
Costa2,3
Maria Alayde Mendonça 
da Silva1,4
Ivan Romero Rivera1,4
Carlos Romério Costa 
Ferro2,4
Alfredo Dias de Oliveira 
Filho4,5
Angelo Mario Bonfim de 
Sá Filho2
Valter Correia de Lima1
1 Federal University of São 
Paulo.
2 State University of Health 
Sciences of Alagoas.
3 University of São Paulo.
4 Federal University of 
Alagoas.
5 Federal University of Sergipe.
Submitted on: 03/01/2013.
Approved on: 12/09/2013.
Correspondence to:
Francisco de Assis Costa.
State University of Health 
Sciences of Alagoas.
Rua Hamilton de Barros Soutinho, 
nº 307, apto. 202, Jatiúca. Maceió, 
AL, Brazil. CEP: 57035-690.
E-mail: facosta@cardiol.br/
fcostahemo@hotmail.com
Tel: (82) 3241-6377/(82) 9308-7146.
IntroductIon
Left ventricular hypertrophy (LVH) is 
an important hypertension-independent 
cardiovascular risk factor, one of its main 
causes.1,2
DOI: 10.5935/0101-2800.20140027
Introduction: Left ventricular hypertro-
phy (LVH) is an independent predictor 
of cardiovascular risk in patients 
with chronic renal disease (CRD) on 
hemodialysis (HD). Objective: To show 
the usefulness of chest radiography in 
the diagnosis of LVH in CRD patients 
on HD. Methods: Cross-sectional 
study including 100 patients (58 men 
and 42 women), mean age 46.2 ± 14.0 
years, with CRD of all causes, for at 
least six months on HD. Were obtained 
echocardiogram and chest x-rays of 
patients, always up to one hour after the 
end of HD sessions. Results: LVH was 
detected in 83 patients (83%), of whom 
56 (67.4%) had the concentric pattern 
and 27 (32.6%) with eccentric pattern 
of LVH. Cardiomegaly - defined by 
cardiothoracic index (CTI) > 0.5 - was 
present in 61 patients (61%). The 
following were the sensitivity, speci-
ficity and accuracy, respectively, for 
the variable ICT: 66.2%, 70.5% and 
68.0%. The Pearson correlation be-
tween ICT and index of left ventricu-
lar mass (LVMI) was 0.552 (p < 0.05) 
and positive likelihood ratio of 2.2. 
Conclusion: Chest radiography is a 
safe and useful as a diagnostic tool of 
LVH in CKD patients on HD.
AbstrAct
Keywords: chest radiography; chronic 
renal disease; hemodialysis; left ventri-
cular hypertrophy.
LVH can be detected by electro-
cardiogram (ECG), chest radiography, 
echocardiogram and magnetic resonance 
imaging. However, in clinical practice, 
ECG and echocardiography are the most 
widely used, not only for reasons of 
availability, but mainly by the prognostic 
association that clearly predicts increased 
cardiovascular risk when LVH is found.3
The aim of this study is to show the 
usefulness of chest radiography in the di-
agnosis of LVH in patients with chronic 
kidney disease (CKD) on hemodialysis, or 
stage 5 CKD, i.e., those with glomerular 
filtration rates of less than 15 ml/min/1.73 
m2 with a need for renal replacement 
therapy),4 correlating the cardiothoracic 
index (CTI) with the left ventricular mass 
index (LVMI) obtained by the transtho-
racic echocardiography - here used as the 
gold standard for comparison.
Methods
From June 2006 to February 2007 
we assessed 133 patients with stage 5 
CKD, of any etiology (see Table 1), cli-
nically stable at an HD program for at 
least six months at the Agro - Sugar and 
Ethanol Industry of Alagoas Hospital 
Foundation. The Ethics Committee on 
Human Research of the State University 
of Health Sciences of Alagoas approved 
the study protocol and all patients sig-
ned an informed consent in accordance 
with the principles of the Declaration of 
Helsinki. The following were the exclu-
sion criteria for the study: history of acute 
or chronic coronary syndrome (regardless 
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of weather), valve disease, cardiomyopathy of any 
origin detected by transthoracic echocardiography, 
pericardial effusion, pacemaker, right or left branch 
block, ventricular pre-excitation syndromes, and any 
other than sinus rhythm. Anyway, any factor that 
could potentially distort left ventricular geometry and 
thus interfere with echocardiographic and radiogra-
phic analysis. Of the 133 patients screened, 33 were 
excluded. Among the 100 selected patients, all were 
interviewed and submitted to casual blood pressure 
measurement, chest radiography and transthoracic 
echocardiography were always carried out within one 
hour after the end of the HD sessions.
analysis. The patient was placed in the left 
lateral decubitus position and we used the Caris® 
echocardiograph (Esaote-Biomedica, Italy) model, 
equipped with a 2.5 MHz transducer, using the 
usual slices thorough the study to obtain the 
M-mode, two-dimensional mode and pulsed 
Doppler, simultaneously with continuous ECG 
recording. According to the recommendations 
from the American Society of Echocardiography/
European Association of Echocardiography,6 
the interventricular septum thickness (IVST) and 
that of the posterior wall of the left ventricle 
(LVPW) were obtained during diastole, and the 
LV mass, in grams, was calculated according to 
the following formula: LV mass = 0.8 x {1.04 
[(IVST + LVDD + LVPW)3 - (LVEDD)3]} + 0.6 g,6,7 
where IVSD is the interventricular septum in 
diastole, LVDD is the LV end-diastolic diameter 
and LVPW is the posterior wall thickness in dias-
tole. The LV mass was corrected for body surface 
area. The echocardiographic diagnosis of LVH was 
established when LVMI was > 88 g/m2 for women 
and > 102 g/m2 for men.5 The left ventricular wall 
relative thickness (WRT) was also calculated by the 
formula: WRT = 2 x LVPW/LVDD, where LVPW 
is the posterior wall of the left ventricle during di-
astole and LVDD is the LV end-diastolic diameter. 
From the calculation of the WRT, it was possible 
to establish the two geometric patterns of LVH: 
tAble 1 cDK etiOlOgy in the sample cOnsiDereD
CKD etiology N = 100
Hypertensive nephrosclerosis (%) 40
Chronic glomerulonephritis (%) 33
Diabetic nephropathy (%) 11
Alport’s syndrome(%) 5
Polycystic kidney disease (%) 4
Lupus nephritis (%) 3
Hydronephrosis (%) 2
Schistosomotic glomerulonephritis (%) 1
Kidney tuberculosis (%) 1
CKD: Chronic kidney disease.
Figure 1. Chest X-ray from patient RAS, 28 years of age, male. Here 
are the points which must be properly utilized to calculate the CTI. 
CTI = A + B/C.
chest X-rays
Chest X-rays were obtained from all patients in 
the orthostatic position, in a posteroanterior view 
(equipment Helliophos 4B®, Germany). We calcula-
ted the CTI, and values > 0.5 defined cardiomegaly. 
Furthermore, we assessed the presence or absence of 
signs of pulmonary congestion. The reproducibility 
status was assessed by reviewing 30 chest radiogra-
phs, taken at random to analyze the CTI variable. 
Figure 1 shows a chest X-ray, in which we see cardio-
megaly and the points considered for the correct CTI 
calculation.
transthOracic echOcarDiOgram
The tests were carried out by two echocardiography 
experts certified by the Echocardiography 
Department of the Brazilian Society of Cardiology, 
strictly following the standards recommended 
by the Guidelines for Indications and Use of 
Echocardiography in Clinical Practice.5 It is note-
worthy that none of these two observers main-
tained any relationship with the chest X-ray 
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tAble 2 DemOgraphic Data/clinical characteristics
Variable N = 100
Age (years) 46.2 ± 14.0
Gender M/F 58/42
Skin color White/Black/Brown 42/35/23
Body surface (m2) 1.6 ± 0.1
Body surface index (Kg/m2) 22.7 ± 3.7
Time in hemodialysis (months) 50.7 ± 46.5
Systemic arterial hypertension (%) 90
Diabetes mellitus (%) 14
Smoking (%) 4
Systolic arterial pressure (mm Hg) 138.2 ± 21.1
Diastolic arterial pressure (mm Hg) 78.1 ± 8.2
Anti-hypertensive drugs
- one 35
- two 24
- three 15
- four 1
M: Male; F: Female.
concentric, when RWT ≥ 0.42; and eccentric, 
when WRT < 0.42.6 The LV systolic function 
was assessed by the percentage shortening of the 
cavity and the LV ejection fraction obtained by the 
Teicholz method.
anthrOpOmetric measures
We checked weight and height, always up to one hour 
after the end of the dialysis sessions. The body surface 
area in m2 was calculated according to the Mosteller 
equation (0.20247 x weight,0.425 height0.725). The body 
mass index was calculated by dividing the weight (kg) 
by height squared (m).
hemODialysis
The patients underwent three weekly dialysis 
sessions, each lasting about four hours. The 
amount of fluid to be withdrawn was measured 
from estimating the “dry weight”, taking into 
account clinical signs of hydration and blood 
pressure behavior during the treatment session. 
The dialysis machines used were the models 
1550 Baxter and AltraTouch (Baxter, USA) with 
cellulose acetate dialyzer regulated by blood flow 
at 250-300 ml/min and 500 ml/min dialysate flow, 
reverse osmosis method.
statistical analysis
Continuous variables were expressed as mean 
and standard deviation. Categorical variables 
were expressed as a percentage. The association 
between LVMI and the other variables of interest 
was made by means of the Pearson correlation 
coefficient. For this study, we considered only re-
levant the Pearson coefficient ≥ 0.50. We used the 
ROC curve to study the CTI sensitivity and spe-
cificity, considering values above 50% as cutoff 
points. The Fisher exact test was used to compare 
CTI sensitivity, according to the geometric pat-
terns of LVH, and we used the Student t-test to 
compare the LVMI of men and women. The CTI 
likelihood ratio was also calculated. The repro-
ducibility test for the studied variable (CTI) was 
performed using the Lin agreement coefficient. To 
check for statistical significance in all compari-
sons, we used the 95% confidence intervals and 
a p < 0.05.
results
Of the 100 patients who completed the study, 58 were 
men (58%) and 42 were women (42%), aged 46.2 ± 14.0 
years (range 18-78 years) and HD duration 50.7 ± 46.5 
months (ranging between six and 225 months, median 
value of 33.5 months). Table 2 summarizes patient 
demographics and clinical characteristics.
LVH prevalence by echocardiography was 83%, with 
56 of these patients (67.4%) with the concentric type and 
27 (32.6%) patients with the LVH eccentric pattern. The 
LVMI in the studied population was 154.9 ± 57.3 g/m2. 
Separating by gender, the LVMI was 159.9 ± 57.0 g/m2 
in men and 148.0 ± 57.6 g/m2 in women (p = 0.306). 
Table 3 shows the values of echocardiographic variables.
tAble 3 DemOgraphic finDings
Variable N = 100 Normal values6
LVDD (mm) 51.1 ± 6.8 39-53
IVS (mm) 51.1 ± 6.8 6.0-9.0
LVPW (mm) 11.7 ± 2.3 6.0-9.0
LV mass (g) 255.1 ± 98.8 67-162
LV mass index (g/m2) 154.9 ± 57.3 43-95
EF (%) 66.7 ± 5.6 ≥ 55
LVDD: Left ventricle diastolic diameter; IVS: Interventricular septum; 
LVPW: Left ventricle posterior wall; EF: Ejection fraction (of the left 
ventricle).
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Criterion assessed Positive LR (CI) Negative LR (CI)
CTI 2.2 (1.21-5.63) 0.4 (0.31-0.78)
tAble 4 cti X lVh liKelihOOD ratiO
LR: Likelihood ratio; CI: Confidence interval; CTI: Cardiothoracic index
Regarding the radiological findings, the 
mean CTI score was 0.53 ± 0.07. Cardiomegaly, 
defined by CTI > 0.5, was present in 61 patients 
(61%) and signs of pulmonary congestion were 
found in 41 cases (41%). The following were the 
sensitivity, specificity and accuracy values for the 
CTI variable in the general population: 66.2% 
(0.555 to 0.755); 70.5% (0.468 to 0.867) and 
68.0% (0.579 to 0.770), respectively. Now, the 
ROC curve for this continuous variable is shown 
in Figure 2. According to the Lin coefficient, levels 
of agreement for the intra - and inter CTI were 
0.91 and 0.90 are considered excellent and good, 
respectively.
dIscussIon
It is assumed that the chest X-Ray is an admittedly 
limited method for LVH diagnosis. In the 
anteroposterior view it is possible to observe 
apex cordis and LV bulging, when there is LVH. 
However; hypertrophy alone does not alter the 
cardiac silhouette as to be detected on chest X-Ray. 
When the LV displays a more pronounced disorder, 
resulting in dilation, the chest radiography may 
grossly show this increase by the cardiothoracic 
index (CTI), which should be more than 0.5.8,9
Under normal conditions, the heart silhouette 
is located in the lower half of the chest, above the 
diaphragm, obliquely to the left, so that one third 
of the cardiac mass lies to the right of the midline 
and two thirds on the left. The sum of the distance 
between the cardiac contour over to the right side 
of the midline with the distance from the left side 
of this boundary line should not exceed half the 
distance of the side edges of the lungs (Figure 1).8,9 
This relationship is defined as CTI, which normal 
value is up to 0.5.8
In the present study the prevalence of cardiomegaly 
was 61 % and the statistical analysis showed a 
correlation between LVMI and CTI, perhaps a 
reflection of the severity of the study population.
However; in the general population, chest 
radiography has not been used for the purpose of 
diagnosing LVH, because it is surpassed by other 
highly available and low cost tools, such as the 
electrocardiogram.
In this study, we used the transthoracic echo-
cardiography as the gold standard test for LVH 
detection. There is no doubt that this imaging 
study represents a major advance in the diagnosis 
of various cardiac pathologies, including LVH. 
However; its high cost and methodological 
limitations with regard to reproducibility, since 
it is very examiner-dependent, restricts its use in 
epidemiological studies, unlike what happens with 
chest radiography and electrocardiography.
It is important to stress that the two tests used 
in our study, the echocardiogram and the chest 
X-ray, were carried out up to an hour after the HD 
session, and there is an estimate that LVMI may 
Figure 2. ROC curve for variable CTI. Area under the curve = 0.734 
(confidence interval = 0.577-0.891).
Proceeding to the Pearson correlation coefficient 
we found a coefficient of 0.552 between the CTI and 
the LVMI (p < 0.05, CI = 0.399 to 0.675).
As seen on Table 4, the calculation of the 
likelihood ratio demonstrates that the CTI has 
discriminatory power in the diagnosis of LVH in 
this population.
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decrease 26 g/m2 on average during the sessions, 
as a consequence of body fluids removal.10
The Framingham study, in a 30-year follow-up, 
showed clearly that the electrocardiogram pattern 
of LVH increased the hazard ratio for coro-
nary events in 3.0 to 5.8 times; of stroke from 3.2 
to 7.0 times and heart failure in up to 17.5 times. 
Particularly in relation to heart failure, the possibility 
of developing it was higher in the presence of an ECG 
compatible with LVH than even a cardiomegaly seen 
on a chest film.11
In this study, the chest film showed good 
performance in LVH diagnosis, with over 66% 
sensitivity, although its specificity was only 70.5%. 
When we divided the population effectively with 
the LVH within the known geometric patterns: 
concentric (worst prognosis) and eccentric, the 
CTI showed no statistically significant difference 
with respect to differentiating one pattern from 
the other, which can be explained by the small 
sample size.
Regarding the Pearson’s correlation coefficient, the 
CTI showed strength, both when one considers the 
general population, as well as when separating by gen-
der, emphasizing that correlation r was higher among 
women, although the mean LVMI was lower in this 
group (148.0 ± 57.6 g/m2 x 159.9 ± 57.0 g/m2; p = 0.306).
Also important is the likelihood ratio calculation, 
which shows discriminatory power in the CTI for 
LVH diagnosis in our sample.
Based on the data presented, it can be 
concluded that, although not among the diagnostic 
procedures of choice for the detection of LVH, the 
study showed that the chest radiography is safe, 
useful, and cannot be neglected as a diagnostic 
tool for LVH in patients with stage 5 kidney 
disease.
limitatiOns Of the stuDy
This is a sample made up of severely ill patients, 
whose clinical profile and the long time in dialysis 
already indicate a high LVH prevalence. Therefore, 
the results presented hereby may not be extrapolated 
to the general population.
Although ventricular mass was indexed to body 
surface, the echocardiography and chest radiography 
were performed within one hour after the end of the 
HD session, the weight reduction is not uniform for 
all patients and there can be variations according to 
the dialysis sessions.
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